In the News

FDA Issues Safety Alert on Avandia

May 21st, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths ... [More >>]

Posted in Avandia, Harmful Drug Exposure, Personal Injury, Product Liability

Driving while asleep among risks of sleeping pills

March 15th, 2007. Drugs included in the label warning update are the following 13 products: Ambien/Ambien CR (Sanofi Aventis) Butisol Sodium (Medpointe Pharm HLC) Carbrital (Parke-Davis) Dalmane (Valeant Pharm) Doral ... [More >>]

Posted in Harmful Drug Exposure, Personal Injury, Product Liability, Sleep Drugs

FDA Requests Label Change for All Sleep Disorder Drug Products

March 14th, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include ... [More >>]

Posted in Harmful Drug Exposure, Personal Injury, Product Liability, Sleep Drugs

Zyprexa & Diabetes (Olanzapine)

July 28th, 2006. Injured by Zyprexa? Side effects of this antipsychotic drug include diabetes, weight gain, hyperglycemia, pancreatitis, and diabetic ketoacidosis. Zyprexa Risks The following are the risks and side effects associated with Zyprexa therapy. This list is not exhaustive. From the FDA web site, Zyprexa's risks include: A life-threatening nervous system ... [More >>]

Posted in Harmful Drug Exposure, Personal Injury, Product Liability, Zyprexa

Serious Eye Infections Prompt Bausch & Lomb To Withdraw ReNu MoistureLoc® Contact Lens Solution From Market

May 18th, 2006. 5/5/06 - FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution 4/13/06 - Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves; and Recommends Consumers Switch to Another Solution Pending Investigation of Reports of Fusarium Infections Among ... [More >>]

Posted in Personal Injury, Product Liability, ReNu MoistureLoc

Bush Republicans Keep Insurance Companies Healthy

May 8th, 2006. With Bush Republicans in the Senate seeking to use their "health" week to push Medical Malpractice legislation that will do nothing to fix the health care crisis in America today, Senate Democratic Leader Harry Reid delivered the following remarks on the Floor of the U.S. Senate. The text of Senator Reid's ... [More >>]

Posted in Medical Malpractice, Personal Injury

FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution

May 5th, 2006. (Press Release) Update on Serious Eye Infections Associated With Soft Contact Lens Use and Contact Lens Solution May 5, 2006. As reported in the MMWR, patients with confirmed cases of Fusarium keratitis have reported using various contact lens cleaning solutions including various types of ReNu products and generics. We continue to confirm reported ... [More >>]

Posted in Personal Injury, Product Liability, ReNu MoistureLoc

Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves; Recommends Consumers Switch to Another Solution Pending Investigation of Reports of Fusarium Infections Among Contact Lens Wearers

April 14th, 2006. (Press Release) Bausch & Lomb (NYSE:BOL) today asked U.S. retailers to remove ReNu® with MoistureLoc® from their shelves temporarily, and recommended that consumers switch to another lens care solution for the time being, until the investigation of reports of fungal keratitis infections among contact lens wearers in the United States is ... [More >>]

Posted in Personal Injury, Product Liability, ReNu MoistureLoc

Merck & Co. deny New England Journal of Medicine’s claims it withheld negative information about arthritis medication Vioxx

December 9th, 2005. An editorial appearing Thursday December 9, 2005 in The New England Journal of Medicine called into question the information provided by Merck for a key study about cardiovascular events caused by the arthritis drug Vioxx. The study called into question was published in November of 2000 for the VIGOR ... [More >>]

Posted in Harmful Drug Exposure, Personal Injury, Product Liability, Vioxx

Vioxx caused Texas man’s death; Merck & Co. required to pay $253 million

August 19th, 2005. Have a Vioxx legal claim? For a free, confidential legal consultation, Submit your Vioxx injury claim or call 1-800-471-3980 now. Of Note: Actual damages: $24.4 Million Punitive Damages: $229 Million $229 Million is the amount Merck made in sales of Vioxx from Oct. 2001, when FDA suggested the label change, to the ... [More >>]

Posted in Harmful Drug Exposure, Personal Injury, Product Liability, Vioxx

« Previous Headlines Newer Headlines »

Copyright 2003 Goldberg, Persky & White, P.C. The information provided by or linked to from this web site is intended to educate and inform victims of asbestos-related disease and other occupational injuries. The Goldberg, Persky & White, P.C. web site is intended for informational purposes only and is not to be construed as medical or legal advice. Visitors who are in need of legal or medical advice should consult with a professional licensed in their state of residence. The opinions expressed herein by persons or organizations other than Goldberg, Persky & White, P.C. are not necessarily endorsed by Goldberg, Persky & White, P.C. No attorney-client relationship is established by visiting our website or sending us Email. Copyright (c) 2003, Goldberg, Persky & White, P.C. All Rights Reserved.